Mehta GU, Vellanki PJ, Ren Y, Amatya AK, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist 2024 Jul 6:oyae151. doi: 10.1093.
PMID: 38970465